Biotech Values

[TastyTheElf]

And these results should put a damper on that thinking since 0.69 is a HR that would have been passed had the trial been running as long as contended (factor of >=2x was the contention) due to treatment being a miraculous cure.

It certainly means that RFA has improved a lot in the last 5 or so years... if the HR was higher than .69 at the interim look, and the modeling is roughly correct (assuming constant hazard rate), I think it forces median control PFS comfortably over 18 months.

That would be consistent with the Chinese meta-analysis we talked about awhile back.